Sinusitis — inflammation of the sinuses — affects millions of people each year in the United States making it one of our most common health problems. It significantly impacts an individual's physical, functional, and emotional quality of life.
Medical therapy can help alleviate symptoms for some patients. However, for 20-25% of sufferers, this form of treatment alone is not adequate. For these patients, sinus surgery is their next hope in finding relief.
While surgery helps many patients, sinuses can become blocked again by inflammation, scarring and sinus tissue growth also known as nasal polyps. This can reduce the long-term effectiveness of the surgery or cause symptoms to return. Propel is breakthrough technology that helps keep sinuses open after surgery while delivering anti-inflammatory medication to the sinus tissue helping patients in both the short- and long-term.
Many cases of sinusitis are acute. However, if the condition occurs frequently or lasts three months or more, it is considered to be chronic sinusitis.
Patients with chronic sinusitis often suffer from facial pain/pressure, nasal congestion, nasal drainage, headaches, loss of the sense of smell and/or taste, loss of sleep, malaise, and depression. For these patients, cold and allergy seasons may seem to last forever.
When the ethmoid sinuses are involved , minimally invasive surgery called functional endoscopic sinus surgery (FESS) to treat the sinus inflammation is the usual surgical option. The ethmoid sinus (one of six sets of sinuses) is located between the nose and eyes.
The Propel sinus stent is FDA approved for use in patients 18 and older following the FESS procedure. Propel is a novel, breakthrough treatment that helps support the newly opened sinus and keep it open. It gradually delivers an anti-inflammatory medicine (mometasome furoate) that reduces inflammation and tissue growth that could block the sinus. Propel holds the sinus open as it heals and delivers medicine right to where it is needed. Not only does it help keep the sinuses open, it reduces the need for additional surgical interventions and/or the need for oral steroids. Within 45 days, as the sinus heals, Propel is designed to completely dissolve.
The device is implanted during sinus surgery where it expands to prop open the sinus, support the bony structures inside the nose and is purported to prevent scar formation. The Propel sinus implant is inserted into the ethmoid sinus cavity by a physician under endoscopic visualization. Upon insertion, the implant expands to conform to the sinus cavity. The delivery system is then removed and discarded. Once Propel is in place, mometasome furoate is released over a 30-day period.
Valley ENT has 22 locations across the Phoenix, Scottsdale, East Valley, West Valley, and Tucson areas to serve you better.